Dr. Walter Maksymowych is a Professor in the Department of Medicine, Division of Rheumatology at the University of Alberta, Alberta, Canada. He is the 2012 recipient of the Distinguished Investigator Award from the Canadian Rheumatology Association. He is also a Medical Scientist of the Alberta Heritage Foundation for Medical Research, Outcome Measures in Rheumatology (OMERACT) steering committee member and Chair of the International OMERACT Soluble Biomarker Working Group, a member of the Canadian Arthritis Network Centres of Excellence, executive member of the Assessments of Spondyloarthritis International Society (ASAS), the Scientific Chair of the Alberta Rheumatoid Arthritis and Pharmacovigilance Program and Outcomes Research in Therapeutics (RAPPORT) committee, and a Principal Investigator and Executive Board member of the Spondyloarthritis Research Consortium of Canada (SPARCC). He is past-Chair of the Scientific Committee of the Canadian Rheumatology Association.
Dr. Maksymowych graduated from the University of Manchester School of Medicine, United Kingdom, in 1981 and completed his postgraduate training at the University of Alberta and the Children's Hospital Medical Center, Cincinnati, Ohio. He holds Fellowships in the Royal College of Physicians of Canada, the American College of Physicians, and the Royal College of Physicians of the UK. His primary research interests are the imaging, genetics, and treatment of spondyloarthritis, and the clinical validation of biomarker technologies for rheumatic diseases. He has published over 200 research articles and is a member of numerous international societies related to arthritis research. His research activities involve a global network of investigators and major partners in the pharmaceutical, imaging, and biomarker industries. He has spearheaded numerous international collaborative networks that have culminated in the development of multiple scoring systems based on imaging and biomarker technologies for use in both diagnostic and therapeutic settings as well as clinical trials research.